Fig. 5

Validation of decreased M2-like macrophages following PAZ@Fe-MOF treatment. (A) Representative immunostaining images of Mrc1 and Cd163 on mice specimens. Scale bars are indicated. (B) Protein levels of Mrc1 and Cd163 were quantified in mice specimens with different treatment. (C-D) Flow cytometry indicated the effects of PAZ@Fe-MOF on the tumor-infiltrating Cd163 + Mrc1 + cells. (E-F) Infiltration of M2-like macrophages in human breast cancer cells MDA-MB-231 treated with the indicated conditions. (G) PAZ@Fe-MOF-RhB nanoagents could be absorbed by IL-4-stimulated RAW264.7 cells. (H-I) The mean fluorescence intensity was quantified. (J) ER was labeled by the ER-tracker. In IL-4-stimulated RAW264.7 cells, the co-localization of PAZ@Fe-MOF with ER were observed with confocal microscopy. *: p-value < 0.05, **: p-value < 0.01